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Aims/Hypothesis: Progressive decline in functional beta-cell mass is central to the development of type 2 
diabetes. Elevated serum levels of extracellular nicotinamide phosphoribosyltransferase (eNAMPT) are 
associated with beta-cell failure in type 2 diabetes, and eNAMPT immuno-neutralization improves glucose 
tolerance in diabetic mice. Despite this, the effects of eNAMPT on functional beta-cell mass are poorly 
elucidated, with some studies having separately reported beta-cell protective effects of eNAMPT.  eNAMPT 
exists in structurally and functionally distinct monomeric and dimeric forms. Dimerisation is essential for the 
NAD-biosynthetic capacity of NAMPT. Monomeric eNAMPT does not possess NAD-biosynthetic capacity, and 
may exert distinct NAD-independent effects. This study aimed to fully characterise the structure-functional 
effects of eNAMPT on pancreatic beta-cell functional mass and relate these to beta-cell failure in type 2 
diabetes. 
 
Methods: We generated recombinant wild-type and monomeric eNAMPT to explore the effects of eNAMPT 
on functional beta-cell mass in isolated mouse and human islets. Beta-cell function was determined by static 
and dynamic insulin secretion and intracellular calcium microfluorimetry. NAD-biosynthetic capacity of 
eNAMPT was assessed by colorimetric and fluorescent assays, and by native mass spectrometry. Islet cell 
number was determined by immunohistochemical staining for insulin, glucagon and somatostatin, with islet 
apoptosis determined by caspase 3/7 activity. Markers of inflammation and beta-cell identity were 
determined by qPCR. Total, monomeric and dimeric eNAMPT and NMN were evaluated by ELISA, western blot 
and fluorometric assay in non-diabetic, glucose intolerant and type 2 diabetes serum 
 
Results: eNAMPT exerts bi-modal, concentration and structure-functional dependent effects on beta-cell 
functional mass. At low physiological concentrations (1 ng/ml), as seen in non-diabetic serum, eNAMPT 
enhances beta-cell function through NAD-dependent mechanisms, consistent with eNAMPT being present as 
a dimer. However, as eNAMPT concentrations rise to 5 ng/ml, as in type 2 diabetes, eNAMPT begins to adopt 
a monomeric form and mediates beta-cell dysfunction, reduced beta-cell identity and number, increased 
alpha-cell number and increased apoptosis, through NAD-independent pro-inflammatory mechanisms.  
 
Conclusions/Interpretation: We have characterised a novel mechanism of beta-cell dysfunction in type 2 
diabetes. At low physiological levels, eNAMPT exists in dimer form and maintains beta-cell function and 
identity through NAD-dependent mechanisms. However, as eNAMPT levels rise, as in type 2 diabetes, 
structure-function changes occur resulting in marked elevation of monomeric eNAMPT, which induces a 
diabetic phenotype in pancreatic islets. Strategies to selectively target monomeric eNAMPT could represent 
promising therapeutic strategies for treatment of type 2 diabetes.  
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Abbreviations: 
[Ca2+]cyt:  Cytosolic calcium 
eNAMPT: Extracellular nicotinamide phosphoribosyltransferase 
FPG:  Fasting plasma glucose  
GSIS:  Glucose stimulated insulin secretion  
IFG:  Impaired fasting glucose 
iNAMPT:  intra-cellular nicotinamide phosphoribosyltransferase 
NMN:  nicotinamide mononucleotide 
NR:  Nicotinamide riboside  
PBEF:  pre-B cell enhancing factor 
SIRT:  Sirtuin 
 
Research in Context: 
What is already known about the subject? 
• Serum concentrations of extra-cellular nicotinamide phosphoribosyltransferase (eNAMPT) are 
elevated in type 2 diabetes.  
• However previous studies have shown both deleterious and protective effects of eNAMPT on the 
pancreatic beta-cell.  
• eNAMPT exists in monomer and dimer forms. Our previous studies have suggested that structure-
functional relationships may mediate the diverse reported effects of eNAMPT. 
 
What is the key question? 
• What are the selective roles of monomeric and dimeric eNAMPT on pancreatic beta cell function and 
mass? 
 
What are the new findings? 
• Serum eNAMPT concentrations increase with progression from normoglycemia to type 2 diabetes. 
However, these increases are not associated with increasing eNAMPT NAD-biosynthetic activity, and 
are characterized by a marked increase in non-NAD biosynthetic monomeric eNAMPT and a relative 
decline in dimeric (NAD synthesizing) eNAMPT. 
 
• At low, physiological levels eNAMPT is present solely in dimeric form and promotes beta-cell function 
through NAD-biosynthetic effects 
 
• As levels of eNAMPT rise to pathophysiological levels (5 ng/ml), as in type 2 diabetes, eNAMPT adopts 
monomeric form and induces beta-cell failure through NAD-independent effects 
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• Monomeric eNAMPT drives beta-cell failure in part through promoting islet inflammation. 
 
How might this impact on clinical practice in the foreseeable future? 
• Developing compounds to selectively target monomeric eNAMPT or stabilise eNAMPT in dimeric form 
could improve functional beta-cell mass and be used to treat type 2 diabetes, through both elevation 


































Elucidating the underlying mechanisms responsible for progressive decline in functional beta-cell mass is 
essential for design of novel treatments for type 2 diabetes (1).   
The protein nicotinamide phosphoribosyltransferase (NAMPT) exists in intra-cellular (iNAMPT) and extra-
cellular (eNAMPT) forms. eNAMPT (visfatin/pre-B-cell enhancing factor) is a circulating protein with several 
reported functions (2-4). Similar to iNAMPT, eNAMPT may exert NAD-biosynthetic effects, whereby eNAMPT 
catalyses the conversion of nicotinamide to nicotinamide mononucleotide (NMN) in serum (5, 6). NMN may 
subsequently be transported into the cell (directly or via conversion into nicotinamide riboside), where it is 
converted into NAD by NMNATs1 – 3. However, this mechanism has been disputed and NAD-independent 
functions, including eNAMPT-mediated pro-inflammatory effects, are also reported (4, 7-9)  
 
Serum eNAMPT levels are elevated in type 2 diabetes, in association with declining beta-cell function. Our in 
vivo studies indicate that eNAMPT may mediate type 2 diabetes pathophysiology (10-12). Contrasting studies 
report that eNAMPT and its reaction product NMN exert beta-cell protective effects via boosting of cellular 
NAD levels (6, 13-19). 
 
A key, but frequently overlooked factor governing eNAMPT function is the presence of structurally and 
functionally distinct monomeric (~52 KDa) and dimeric (~104 KDa) eNAMPT. Dimerization is essential for NAD-
biosynthetic capacity of eNAMPT (6, 20), and eNAMPT-dimer predominates in normal physiology [12,15]. 
eNAMPT-monomer does not possess NAD-biosynthetic capacity and may mediate NAD-independent pro-
inflammatory effects. Our studies suggested a specific pathophysiological role for monomeric eNAMPT in 
diabetic mice (12). We hypothesised that in type 2 diabetes, eNAMPT-monomer is selective elevated, which 
exerts NAD-independent pro-inflammatory effects, and that this, combined with loss of eNAMPT NAD-
biosynthetic capacity plays a key role in disease pathophysiology. 
 
However, whether eNAMPT-monomer is elevated in T2D, and to what extent the structurally distinct forms of 
eNAMPT directly affect the pancreatic beta-cell are unknown. Previous studies, including our own, have 
examined NAD-boosting effects of NMN on beta-cell function (6, 13, 14), or have examined supraphysiological 
concentrations or acute effects of eNAMPT (21, 22), neither of which accurately mimic in vivo 
(patho)physiology. Of perhaps greater importance, the selective effects of monomeric and dimeric eNAMPT 
on beta-cell health have not been examined.  
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We used isolated mouse and human islets, and human type 2 diabetes serum, to specifically characterise 
effects of monomeric and dimeric eNAMPT on pancreatic beta-cell functional mass. 
 
Materials and Methods 
Animals 
Eight-week-old male CD1 mice (28-33 g; Envigo, UK) were housed in 12-hour light/dark cycle temperature-
controlled conditions with ad libitum access to standard mouse chow and water. Procedures were performed 
in accordance with U.K. Home Office regulations (Animal Scientific Procedures Act, 1986). 
 
Human samples 
Human serum was obtained from obese non-diabetic, IFG and type 2 diabetes individuals, as part of the 
BodyFatS&H study (University of Auckland, New Zealand) and separately from the VaSera trial(23) (St Thomas’ 
Hospital, London). Study participants gave informed consent. Investigations were approved by NRES 
Committee- London Central (VaSera) and NREC, Auckland, New Zealand (BodyFatS&H). ESM Methods 
 
Native Mass Spectrometry 
Native Mass Spectrometry was conducted using Synapt G2S HDMS (Waters, Manchester, UK).  ESM Methods. 
 
eNAMPT protein generation 
Recombinant wild-type eNAMPT (eNAMPT-WT) and mutant SS199/200DD (eNAMPT-monomer) were produced 
in E.Coli. ESM Methods. 
 
Pancreatic islet isolation and insulin secretion 
Mouse islets were isolated between 9 – 10 am, (24). Human islets were isolated from heart-beating non-
diabetic donors, with ethical approval, at the King’s College Hospital Human Islet Isolation Unit (24). All isolated 
islets were incubated overnight (37°C, 5% CO2) prior to treatments. 
 
Static and dynamic glucose-stimulated insulin secretion 
Static or dynamic insulin secretion was assessed in response to 2 or 20 mmol/l glucose exposure, as previously 







Endotoxin concentrations were measured in recombinant eNAMPT preparations using the Pierce LAL 
Chromogenic Endotoxin Quantitation Kit (ThermoFisher Scientific). 
 
In vitro islet immunostaining  
Mouse islets were pelleted and fixed in 4% (vol/vol) buffered formalin. Sections (5 mol/l) were incubated 
with anti-guinea pig insulin, anti-rabbit glucagon or anti-rabbit somatostatin (all Dako, 1:100) and DAPI 
(ThermoFisher). Secondary antibodies used were: AlexaFluor 488-labelled goat anti-mouse, AlexaFluor 594-
labelled donkey anti-guinea-pig and AlexaFluor 488-labelled donkey anti-rabbit (1:200; all Jackson 
ImmunoResearch). Sections were mounted on glass slides and captured on a Nikon TE2000 fluorescent 
microscope and quantified using Image J.  
 
Islet apoptosis 
Mouse islets were treated with eNAMPT +/- cytokine cocktail (0.05 U/μl Il-1β, 1U/μl TNFα and IFNγ; 48 h). 
Apoptosis was determined by Caspase-Glo 3/7 luminescent assay (Promega, Southampton, UK). 
 
Quantitative RT-PCR  
Gene expression was determined by Sybr Green qRT-PCR using ΔΔCt methodology, normalised against GAPDH 
(Quantitech, UK). ESM Methods/ESM Table 1. 
 
Intracellular calcium [Ca2+]cyt 
Whole mouse islets, incubated in HEPES bicarbonate buffer (containing 2 – 20 mmol/L glucose), were loaded 
with Fura-2AM and imaged using a Nikon Ti-E microscope equipped with FuraLEDs (Cairn Research) (excitation 
= 340/385 nm, emission = 470-550 nm).   
 
MIN6 cell culture  
MIN6 cells (mycoplasma free) were cultured at 37°C in DMEM (25 mmol/l glucose; 2 mmol/l glutamine, 10% 
FBS, 100U/ml penicillin, 100μg/ml streptomycin) and treated with eNAMPT or NMN (48 h), prior to NAD and 
NMN measurements.  
 
eNAMPT Immunoblotting 
Serum eNAMPT-monomer and dimer were measured by immunoblotting, under non-reducing conditions, as 




eNAMPT, NAD and NMN measurements 
Total serum eNAMPT was measured by ELISA (Adipogen, Seoul, South Korea). MIN6 intracellular NAD and 
NMN levels were measured by NAD/NADH quantification kit, (Sigma-Aldrich, Poole, UK) and in-house 
fluorometric assay, respectively (27, 28).  ESM methods. 
 
Data Analysis 
Data is expressed as mean ± SEM. Significance was tested using one or two-way ANOVA with Tukey’s or Sidak’s 





Serum eNAMPT-monomer concentrations are elevated in type 2 diabetes and are positively correlated with 
increased HbA1c 
 
We first demonstrated that serum eNAMPT concentrations increased with progression of type 2 diabetes (Fig. 
1a).  In obese non-diabetic individuals, serum eNAMPT concentrations were 1.7 +/- 0.4 ng/ml; rising to 3.4 +/- 
0.7 ng/ml in IFG, and 4.6 +/- 0.6 ng/ml in type 2 diabetes (P<0.05 vs. non-diabetic). These concentrations are 
similar to those observed in previous studies (29, 30)(31). Increasing eNAMPT concentrations strongly 
correlated (R2=0.3787; P<0.01) with increasing HbA1c (mmol/mol), indicating a role of eNAMPT in mediating 
poor glycaemic control (Fig. 1b). Next, we specifically measured serum eNAMPT-monomer and -dimer by 
immunoblotting under non-reducing conditions. eNAMPT-monomer was almost absent in ND serum, but 
increased markedly in T2D. Specifically, in ND serum, eNAMPT was 95.8% dimer and 4.2% monomer, but in 
T2D serum eNAMPT was 71% dimer and 29% monomer which translated into a concentration of 1.83 ng/ml 
eNAMPT-monomer in T2D serum (Fig 1c-e). Increasing eNAMPT concentrations did not correlate with serum 
NMN levels and NMN was not associated with HbA1c (Fig. 1g-f). This suggests a selective pathophysiological 
role for eNAMPT-monomer in T2D. Neither eNAMPT nor NMN were correlated with BMI, age or serum insulin 
(ESM Fig. 1).  
 
eNAMPT exerts bi-modal effects on beta-cell function in mouse and human pancreatic islets 
 
Increased HbA1c is indicative of poor glycaemic control and deteriorating beta-cell function. To assess the 
(patho)physiological effects of eNAMPT on beta-cells, we used serum eNAMPT concentrations (as detected in 
Fig 1A and (12)), and exposed isolated islets to physiological (1 ng/ml)) and pathophysiological (5 ng/ml) 
eNAMPT. To account for batch-to-batch differences between commercially available eNAMPT (8), we 
generated recombinant wild-type eNAMPT (eNAMPT-WT). To specifically examine eNAMPT-monomer, we 
mutated Ser199/200 (key residues in the NAMPT binding interface (6, 20)) to aspartic acid. This generated a 52 
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KDa protein (eNAMPT-monomer), which neither dimerized correctly, as demonstrated by size-exclusion 
chromatography and native MS, nor synthesised cellular NMN and NAD (ESM Fig. 2a-e). Neither eNAMPT-WT 
nor eNAMPT-monomer contained notable endotoxin concentrations (ESM Fig. 2f) 
 
eNAMPT-WT induced a bi-modal response. 1 ng/ml eNAMPT significantly enhanced static glucose-stimulated 
insulin secretion (GSIS) in mouse and human islets (24-48 h; Fig. 2a-b,e-f) and enhanced dynamic GSIS (48 h; 
P<0.05; Fig. 2h-i) and intra-cellular calcium levels ([Ca2+]cyt,) in mouse islets (Fig. 2l-m; AUC P<0.01). In contrast, 
neither 5 ng/ml eNAMPT-WT nor eNAMPT-monomer (0.1-5 ng/ml; 48 h) stimulated static or dynamic GSIS or 
increased intra-cellular calcium in mouse or human islets, with levels similar to or reduced compared 
untreated islets (Fig. 2a-m).  A similar bi-modal insulin secretory response was observed following exposure 
to commercial eNAMPT (Adipogen, Seoul, South Korea) (ESM. 3a-c).  
 
We also assessed effects of a combination of eNAMPT-WT and eNAMPT-monomer, which is more 
representative of normal (patho-)physiology. eNAMPT-WT (1 ng/ml) alone induced GSIS as expected; 
however, when eNAMPT-WT (1 ng/ml) was added in combination with eNAMPT-monomer, the insulin 
stimulatory effects of eNAMPT-WT were lost (Fig 2n).  
 
Together this demonstrates that low, physiological eNAMPT enhances beta-cell function, but as eNAMPT rises 
to pathophysiological levels (5 ng/ml), beneficial effects are lost and eNAMPT mediates beta-cell dysfunction. 
The effects of high concentrations of eNAMPT-WT are mimicked by non-dimerising eNAMPT-monomer, 
consistent with the notion that eNAMPT-WT adopts monomeric structure and function at higher 
concentrations. 
 
Pathophysiological eNAMPT reduced beta-cell number and identity and increased alpha-cell number 
Type 2 diabetes is characterised by reduced beta-cell mass, with loss of beta-cell identity, and increased 
apoptosis possible mechanisms. Consistent with the bi-modal insulin secretory response, mRNA levels of islet 
INS2 and the essential beta-cell identity markers (32) PDX1, NKX2.2 (P<0.01) and NKX6.1 (P<0.05) (Fig. 3a-b) 
were increased by 1 ng/ml eNAMPT-WT but not  5 ng/ml eNAMPT-WT, nor 1 ng/ml eNAMPT-monomer (48h; 
Fig. 3a-c). 5 ng/ml eNAMPT-WT also enhanced cytokine-mediated islet apoptosis, (caspase3/7 activity) 
(p<0.001, Fig. 3d), as well as significantly reducing insulin+ cells and increasing glucagon+ (P<0.05) and 
somatostatin+ cells denoting decreased beta-cell and increased alpha- and delta-cell number, respectively (Fig. 
3e–k; ESM Fig 4).  
 
eNAMPT impairs beta-cell function via pro-inflammatory mechanisms 
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Pro-inflammatory effects of eNAMPT are reported, although to date, not in type 2 diabetes. eNAMPT-WT at 5 
ng/ml, but not 1 ng/ml (48 h) increased mouse islet Il1B (P<0.05) and CCL2 (P<0.001) gene expression (Fig. 4a). 
Similarly, eNAMPT-monomer (1 ng/ml; 48 h) increased Il1B and CCL2 gene expression in mouse and human 
islets (P<0.05) (Fig. 4b). Inflammatory pathway inhibitors (Tocris Biosciences, Abingdon UK) demonstrated that 
inhibition of STAT3 (using NCS74859) and P38-MAPK (using SB203580), but not of NFB (using BAY 11-7082) 
or JNK (using SP600125), blocked the inhibitory effects of eNAMPT on GSIS (Fig. 4c).  
 
Therefore, pathophysiological concentrations of eNAMPT-WT and eNAMPT-monomer induce beta-cell 
dysfunction, in part through promotion of STAT3 and P38-mediated islet inflammation. 
 
Structure-function changes mediate bi-modal effects of eNAMPT-WT  
Since the effects of eNAMPT-monomer were mimicked by 5 ng/ml, but not 1 ng/ml eNAMPT-WT, we 
hypothesised that high concentrations of eNAMPT-WT (5 ng/ml) would be associated with reduced NAD 
biosynthetic capacity (compared to 1 ng/ml) indicative of reduced eNAMPT-dimer and increased eNAMPT-
monomer levels.  
 
In support of this, 1 ng/ml eNAMPT-WT (48 h) increased cellular NMN and NAD, 30% (P<0.05) and 20% above 
basal levels, respectively, in MIN6 cells. These changes were mimicked by NMN treatment (100 mol/l; 48 h; 
Sigma‐Aldrich, Poole, UK) (Fig 5a-d). NMN also mimicked functional effects of 1 ng/ml eNAMPT-WT, 
significantly increasing levels of GSIS and INS2, NKX2.2 and PDX1 mRNA (Fig. 5e–f). In contrast, and similar to 
effects of eNAMPT-monomer, 5 ng/ml eNAMPT-WT did not increase cellular NMN nor NAD (Fig. 5a-d; ESM 
Fig. 2d-e). Furthermore, AMCP-mediated inhibition of CD73 (a protein involved in cellular NMN uptake) (33-
36)(37) inhibited the insulin secretory effects of 1ng/ml eNAMPT-WT (P<0.05), but had no effects on the 
inhibitory actions of 5 ng/ml eNAMPT-WT on GSIS (Fig. 5g).  Thus, 1 ng/ml eNAMPT induces NAD biosynthesis 
and requires islet NMN uptake to exert functional effects. In contrast, effects of 5 ng/ml eNAMPT were 
unaffected by inhibition of NMN uptake, suggesting an NAD-independent pathway.  
 
This data provides evidence that the bi-modal effects of eNAMPT-WT are related to loss of NAD-biosynthetic 
capacity of eNAMPT at higher concentrations.  
 
Discussion  
This study demonstrates that eNAMPT exerts bi-modal, concentration and structure-function dependent 
effects on pancreatic beta-cell functional mass, and provides clarification of previous contradictory eNAMPT 
studies. 
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Low, physiological levels of eNAMPT (1 ng/ml) enhance beta-cell health through NAD-dependent mechanisms. 
Since islets are continually exposed to low eNAMPT concentrations in healthy non-diabetic individuals, this 
indicates a role for low eNAMPT concentrations in maintaining beta-cell health. Beta-cell identity genes were 
increased at 1 ng/ml eNAMPT, highlighting the potential importance of physiological eNAMPT in maintaining 
beta-cells in fully differentiated state, consistent with studies showing beta-cell de-differentiation following 3-
day culture in the absence of circulating factors, including eNAMPT/NMN (41). The effects of 1 ng/ml eNAMPT 
are mediated via NAD-biosynthesis, suggesting eNAMPT exists in dimeric form at lower concentrations. This 
is consistent with our observations in non-diabetic human and mouse serum which show eNAMPT-dimer as 
the predominant structural form at low physiological concentrations (12). Whether eNAMPT can exert NAD-
biosynthesis within extra-cellular space remains controversial. Whilst RPMI media contains sufficient 
nicotinamide to support eNAMPT enzymatic activity, we were unable to detect eNAMPT within spent islet 
media after eNAMPT incubation, suggesting that at least some eNAMPT-dimer is taken up into the islet/beta-
cell, after which NMN synthesis occurs intra-cellularly.  
Mechanistically, eNAMPT-mediated NAD synthesis may improve beta-cell health through activation of NAD-
dependent sirtuins or via actions of NAD metabolites cADPR and NAADP which reportedly induce intra-cellular 
calcium mobilisation  (13, 14, 16, 19).  
 
Conversely, as eNAMPT concentrations rise to pathophysiological levels, as in type 2 diabetes, eNAMPT 
induces islet inflammation, and initiates beta-cell dysfunction, beta-cell death and reduced beta-cell mass and 
identity. The mechanisms driving reduced beta-cell number and identity are unclear. We have demonstrated 
that high concentrations of eNAMPT enhance beta-cell apoptosis, however beta- to alpha-cell trans-
differentiation or beta-cell de-differentiation, may also play a role, and further studies are required to identify 
the precise mechanisms. 
 
eNAMPT exerts beta-cell dysfunction through NAD-independent mechanisms, suggesting a switch toward 
monomeric eNAMPT at higher concentrations. This is consistent with observations that eNAMPT-monomer 
was present at 1-2 ng/ml in T2D serum, but almost absent in non-diabetic serum, and also consistent with our 
observations that increasing serum eNAMPT did not correlate with increasing serum NMN. 
 
Whilst elevated eNAMPT strongly correlated with increased HbA1c, we did not observe notable correlations 
between eNAMPT and BMI, and only a weak correlation between eNAMPT and serum insulin. We hypothesise 
that as glucose rises during glucose intolerance, secretion of eNAMPT-dimer increases, which promotes islet 
compensation. However, as eNAMPT levels continue to rise in response to elevated glucose, eNAMPT-dimer 
begins to break apart into constituent eNAMPT-monomers, which then drive beta-cell failure. Thus, eNAMPT 
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increases strongly correlate with increases in blood glucose and HbA1c, and do not necessarily precede 
hyperglycaemia. Precisely why eNAMPT preferentially exists as a monomer at high levels remains unclear but 
may relate to ligand-induced dimerization, whereby eNAMPT is stabilised and maintained in dimer form by 
the presence of an endogenous ligand.  We hypothesise that insufficient concentrations of the putative ligand 
at higher eNAMPT concentrations lead to break up the dimer into constitutive monomers.  
Mechanistically, eNAMPT promoted islet inflammation and beta-cell failure, through P38-MAPK and STAT3 
pathways. Similar eNAMPT effects are reported in macrophages, monocytes and islets of HFD mice (7, 9, 12, 
38).  Upstream, these effects may be receptor-mediated, with eNAMPT reported to function via TLR4 (39), 
CCR5 (40), IGF and IR (8) signalling, although these remain unconfirmed. Separately, the deleterious effects of 
eNAMPT-monomer may also reflect decreased eNAMPT-dimer mediated NAD synthesis, occurring separately 
from direct effects of eNAMPT-monomer.  
 
Together, our results characterise structure-functional relationships as being of crucial importance to the 
effects of eNAMPT on beta-cell health. Moreover, we demonstrate a novel mechanism of beta-cell dysfunction 
in type 2 diabetes. Strategies to block actions of eNAMPT-monomer by promoting dimerization or stabilizing 
eNAMPT in dimer form could represent promising therapeutic approaches for treatment of diabetes.  
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Figure 1: Serum eNAMPT levels are increased in type 2 diabetes and are associated with increased HbA1c. 
Serum was collected from non-diabetic, IFG and type 2 diabetic individuals and eNAMPT was measured by 
ELISA. (a) Serum eNAMPT (data generated from BodyFatS&H and VaSera trial samples); (b) Serum eNAMPT 
vs. HbA1c (mmol/mol) (data generated from VaSera trial only). (c) Western blot of serum eNAMPT monomer 
and dimer; (d) Percentage ratio of eNAMPT monomer and dimer in ND and T2D serum; (e) Calculated 
concentration of eNAMPT-monomer and dimer in T2D serum; (f) Serum NMN; (g) Serum NMN vs HbA1c 
(mmol/mol) (data generated from VaSera trial only); ND = obese non-diabetic (BMI>30 kg/m2; FPG = <5.6 
mmol/L) (n=13); IFG (impaired fasting glucose; FPG 5.6 – 6.9 mmol/L; BMI>30 kg/m2) (n=15); type 2 diabetes 
(FPG>7.0 mmol/L; BMI>30 kg/m2) (n=27). N is equal to 1 individual. N values differ for NMN measurements 
due to limited sample availability for some samples. Data are expressed as means ± SEM. * P<0.05; **P<0.01, 
calculated by 1-way ANOVA with Tukey’s post-test, or Pearson correlation. Western blots are representative 
of 3 separate blots. To ensure equivalent loading of each gel lane, serum protein was equalized to 10 g and 











































































































































Figure 2: Glucose-stimulated insulin secretion has a bi-modal response to eNAMPT. (a – d) Static insulin 
secretion in response to basal (2 mmol/l) or 20 mmol/l glucose was assessed in isolated mouse islets incubated 
with 1 – 5 ng/ml eNAMPT-WT for (a) 24 and (b) 48 h or with 0.1 – 5 ng/ml eNAMPT-monomer for (c) 24 h and 
(d) 48 h; (e) Static insulin secretion in response to 20mM glucose was assessed in isolated mouse islets 
incubated with 1 – 5 ng/ml eNAMPT-WT and eNAMPT-monomer. (f – g) Static insulin secretion in response to 
basal (2 mmol/l) or 20 mmol/l glucose was assessed in isolated human islets incubated with 1 – 5 ng/ml 
eNAMPT-WT or 0.1 – 5 ng/ml eNAMPT-monomer for 48 h. For static GSIS, n=5 – 28, where an n of 1 = 5 
islets/incubation tube, repeated 8 – 10 times. (h – k) Dynamic insulin secretion was assessed in isolated mouse 
islets incubated with (h-i) 1 – 5 ng/ml eNAMPT-WT or with (j-k) 1 – 5 ng/ml eNAMPT-monomer for 48 hours 
by perifusion with 2 mmol/l or 20 mmol/l glucose and 20 mmol/l KCl. For perifusion, n= 9-12, where an n of 1 
equals one perifusion of 160 islets isolated from 4 – 6 mice); (l – m) Glucose-stimulated [Ca2+]cyt was measured 
in isolated mouse islets treated with 1 – 5ng/ml eNAMPT-WT for 48 hours, (n= 3 mice/treatment, 9-16 
islets/treatment). (n) Static insulin secretion in response to basal (2 mmol/l) or 20 mmol/l glucose was 
assessed in isolated mouse islets incubated with a combination of 1 ng/ml eNAMPT-WT and 1 ng/ml eNAMPT-
monomer for 48 hours (n= 4-19). (a – g,n) grey bars = 2 mmol/l glucose; black bars = 20 mmol/l glucose; (h,j, 
l) black = untreated;  blue = 1ng/ml eNAMPT-WT; grey = 5 ng/ml  eNAMPT-WT; (k,m) black lines = untreated; 
blue lines = 1 ng/ml eNAMPT-monomer; grey bars = 5 ng/ml eNAMPT-monomer.  Data are expressed as means 
a b c d e
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± SEM, (a-d; f-n) *P<0.05 (vs. 1 ng/ml eNAMPT-WT), **P<0.01 (vs. 1 ng/ml eNAMPT-WT), ***P<0.001, by 1- 
and 2-way ANOVA. (e) ***P<0.001 vs untreated (WT); ††† P<0.001 vs 1 ng/ml eNAMPT-WT by 1- way ANOVA; 
































Figure 3: Monomeric eNAMPT mediates reductions in beta-cell identity and number (a – c) Gene expression 
of Nkx2.2, Nkx6.1, Pdx1, INS2 was measured in mouse islets were treated with (a – b) 1 – 5 ng/ml eNAMPT-
WT or (c) 1 ng/ml eNAMPT-monomer for 48 h; (d) Apoptosis: Caspase-3/7 activity was measured in islets 
treated with eNAMPT-WT with/without a cocktail of cytokines (TNFα, IFNγ and IL1β) (n= 7-16); (e – k) Mouse 
islets were treated with 1 – 5 ng/ml eNAMPT-WT for 48 h (e) Double immunofluorescence images of islets 
stained for insulin (green) and DAPI (blue) (f) % DAPI/insulin positive stained cells (n=3, where n of 1 = 200 – 
300 islets from one mouse); (g) Double immunofluorescence images of islets stained for glucagon (red) and 
DAPI (blue) (h) % DAPI/glucagon positive stained cells (n=3); (i) Immunofluorescence images of islets stained 
for insulin (green), glucagon (red) and DAPI (blue) (j) % DAPI/glucagon:% DAPI/insulin stained cells (n=3); (k) 
% GLU+/INS+ bi-hormonal cells (a, b) black = untreated;  blue = 1ng/ml eNAMPT-WT; grey = 5 ng/ml; (c) black 
bars = untreated; grey bars = 1 ng/ml eNAMPT-monomer; (d) black bars = no cytokines; grey bars = with 
cytokines. eNAMPT-WT Data are expressed as means ± SEM, *P<0.05, #P<0.05 (vs. 1 ng/ml eNAMPT-WT), 





































































































































































































Figure 4: Monomeric eNAMPT impairs GSIS via pro-inflammatory mechanisms (a) Gene Expression of CCL2, 
TNFA and IL1B in mouse islets after treatment with eNAMPT-WT (n=4-5). (b) Gene Expression of CCL2, TNFA 
and IL1B in mouse and human islets after treatment with eNAMPT-monomer (n=4-5). (c) Mouse islets were 
treated with 5ng/ml eNAMPT-WT or 1ng/ml eNAMPT-monomer in combination with inhibitors of P38 
(SB203580; 1 mol/l), STAT3 (SB203580; 50 mol/l), JNK (SP600125; 50 mol/l) or NFκB (BAY 11-7082; 1 
mol/l) for 48 h and insulin secretion was measured after static incubation in 2 mmol/l (not shown) or 20 
mmol/l glucose (n = 8-10). Data are expressed as means ± SEM. (a) black bars = untreated; green bars = 1 
ng/ml eNAMPT-WT; grey bars = 5 ng/ml eNAMPT-WT; (b) black bars = untreated; grey bars = 1 ng/ml eNAMPT-
monomer; (c) black bars = no inhibitor; purple bars = SB203580; grey bars = SB203580; blue bars = SP600125, 
brown bars = BAY 11-7082  Panel a and b:  *P<0.05, **P<0.01, ***P<0.001; Panel c: :  *P<0.05, **P<0.01 




















































































Figure 5: Structure-function changes mediate the bi-modal effects of eNAMPT-WT (a - d) MIN6 cells were 
incubated with either NMN (100 mol/l) or eNAMPT-WT (1 – 5 ng/ml) for 48 h; (a – b) intra-cellular NMN, (c 
–d) intra-cellular NAD (n=5 -10, where n of 1 = 1 well of a 12 well plate). (e-f) Mouse islets were treated with 
NMN (100 mol/l) (E) Static insulin secretion in response to 2 and 20 mmol/l glucose (n=5); (f) Gene expression 
levels of PDX1, INS2 and NKX2.2 measured by qPCR (n=5-12). (g) Mouse islets were treated for 48 h with 
eNAMPT-WT (0.5 – 5 ng/ml) in combination with the CD73 inhibitor AMCP, and static insulin secretion was 
measured in response to 20mM glucose (n=17). (f-g) black bars = untreated; grey bars = NMN. Data are 




















































































































































































































































Human serum samples were obtained from obese non-diabetic individuals (BMI: 46.4 +/- 1.8 kg/m2; 
FPG: <5.6 mmol/L; Age: 53.0 +/- 2.0 years; n=13) and obese individuals with IFG (BMI: 37.5 +/- 
1.9 kg/m2; FPG 5.6 – 6.9 mmol/L; Age: 54.9 +/- 3.3 years; n=15) and type 2 diabetes (BMI: 36.3 +/- 
1.6 kg/m2; FPG ≥7.0 mmol/L; Age: 41.5 +/- 3.5 years; n=27), as part of the Body Fat, Surgery and 
Hormone study (BodyFatS&H) conducted at the University of Auckland, New Zealand 
(NTX/08/10/103; Northern Regional Ethics Committee, Auckland, New Zealand) and as part of the 
VaSera trial [1], conducted at St Thomas’ Hospital, London (ISRCTN25003627; NRES Committee- 
London Central, 21/12/2012, ref: 12/LO/1850). VaSera trial participants consisted of individuals with 
type 2 diabetes or those at risk of developing type 2 diabetes (FPG: 5.6 – 6.9 mmol/L; BMI >30 
kg/m2). 
Native Mass Spectrometry 
The protein was expressed and isolated as previously described and, on the day of analysis, the buffer 
was exchanged into 100 mM ammonium acetate (Fisher Scientific, Loughborough, UK) pH 6.9 using 
micro Bio-Spin Chromatography columns (Bio-Rad, Micro Bio-Spin 6 Columns) following the 
instructions specified by the manufacturer. The procedure was repeated twice and diluted to give a 
final concentration of WT NAMPT (5 mol/l) or S200D NAMPT (5 mol/l).  Native MS data was 
acquired on the Synapt G2S HDMS (Waters, Manchester, UK).  NanoESI capillaries were prepared 
in-house from thin-walled borosilicate capillaries (inner diameter 0.9 mm, outer diameter 1.2 mm, 
World Precision Instruments, Stevenage, UK) using a Flaming/Brown P-1000 micropipette puller 
(Sutter Instrument Company, Novato, CA, USA).  A positive voltage was applied to the solution via a 
platinum wire (Goodfellow Cambridge Ldt, Huntington, UK) inserted into the capillary.  Gentle source 
conditions were applied to preserve the native-like structure: capillary voltage 1.2-1.5 kV, sampling 
cone 50-200 V, source temperature 70 °C.  Trap collision energy was 4 V, transfer collsion energy was 
set to 0 V. Nitrogen was the carrier gas. External calibration of the spectra was achieved using solutions 
of cesium iodide (2 mg/mL in 50:50 water:isopropanol). Data were acquired and processed with 
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Construction of DNA plasmids: DNA for full length mouse NAMPT was synthesised as a double 
stranded DNA gBlock (Integrated DNA Technologies) and cloned into pET151 according to 
manufacturer’s instructions (ThermoFisher).  This vector adds an N-terminal 6xHis and V5 tag, and a 
TEV cleavage site, giving an extra 33 amino acids on the N-terminus of the protein.  Mutagenesis was 
carried out to change residues S199 and S200 to D199 and D200 using the overlapping primers 
GGTTACAGAGGAGTCGACGATCAAGAGACTGCTGGC and 
GCCAGCAGTCTCTTGATCGTCGACTCCTCTGTAACC, and the Quikchange lightning kit 
(Agilent Technologies) according to the manufacturer’s instructions.  The constructs and mutations 
were verified by sequencing (Eurofins Genomics). 
Expression of NAMPT wild type and eNAMPT-monomer (SS199/200DD) mutation: For expression, 
the constructs were transformed into BL21 Star (DE3) E. coli (ThermoFisher).  Colonies were used to 
inoculate a starter culture in Luria Broth containing 100ug/mL ampicillin, and left shaking at 37oC for 
5 hours.  This was used to inoculate 200mL ZYP-5052 autoinduction media (Studier, 2005) and the 
culture grown at 18oC shaking for 65 hours. The bacteria were harvested by centrifugation at 4000g 
and frozen at -80oC.  
Purification of eNAMPT-WT and eNAMPT-WT (SSDD) mutation: Pellets were thawed and EDTA 
Complete protease inhibitor tablets added (Roche) then the E. coli were lysed using BugBuster (Merck 
Millipore, Burlington, MA, USA) according to the manufacturer’s instructions.  The NAMPT was 
found in the soluble fraction and was purified by passing over a 1mL Histrap ff crude column (GE 
Healthcare, Chicago, IL, USA) using a Biorad NGC system.  The column was washed with 30 column 
volumes of 10mM sodium phosphate, 500 mmol/l NaCl, 20 mmol/l imidazole pH 7.4 and the bound 
protein eluted with 10 mmol/l sodium phosphate, 500 mmol/l NaCl, 500 mmol/l imidazole pH 7.4.  
Fractions containing protein were then pooled and concentrated (Amicon Ultra 15, Merck Millipore), 
then further purified using size exclusion chromatography.  Using a Gilson HPLC system, samples 
were run on a Superdex 200 increase 10/300 GL column in Phosphate buffered saline pH 7.4 (OXOID).  
Fractions corresponding to monomer and dimer were pooled individually.  Final yield of protein was 





Pancreatic islet isolation  
Mouse CD1 Islets were isolated as described previously [2]. Pancreata were inflated with 1mg/mL 
collagenase solution (Sigma-Aldrich, Poole, U.K.) followed by density gradient separation 
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(Histopaque-1077; Sigma-Aldrich). Human islets were isolated from heart-beating non-diabetic 
donors, with appropriate ethical approval, at the King’s College Hospital Human Islet Isolation Unit 
[2]. Isolated islets were incubated overnight (37°C, 5% CO2) prior to treatments. See human islet 
checklist table for additional details of human islet preparations. 
Static and dynamic glucose-stimulated insulin secretion 
For static insulin secretion, mouse CD1 or human islets were pre-incubated in a physiological salt 
solution [3] containing 2mM glucose. Groups of 3-5 size-matched islets were then further incubated 
at 37°C for 1 h in salt solution and 2 or 20 mmol/l glucose. Dynamic insulin secretion was measured 
using a temperature-controlled perifusion system. Mouse CD1 islets were transferred into chambers 
containing 1 μm pore-size nylon filters (40 islets/chamber) and perifused with a physiological salt 
solution [3] (37°C, 0.5mL/min) containing 2 or 20 mmol/l glucose or 20 mmol/l glucose and 20 mmol/l 
KCl. Samples were collected at 2-minute intervals throughout the experiment. Secreted insulin was 
measured using an in-house I125 radioimmunoassay [3]. 
 
Quantitative RT-PCR  
Total mouse CD1 or human islet RNA was extracted using Trizol reagent (Invitrogen, Paisley, UK). Reverse 
transcription was performed using the High-Capacity cDNA reverse transcription kit (Applied Biosystems, 
Warrington, UK). Real-time qPCR was carried out with a LightCycler480, using Sybr Green PCR master mix 
(Qiagen, Hilden, Germany). Gene expression was measured by ΔΔCt methodology, normalised against GAPDH 
(Quantitech, UK). For primer details (all Eurogentec, Southampton, UK) see ESM Table 1. 
 
NMN measurements 
NMN was measured in MIN6 cells and human serum using a fluorometric assay based on previous 
described methodology [4,5].  MIN6 or serum samples (30 L) were extracted with 100 μL perchloric 
acid (1 mol/L) and then neutralized by addition of 330 L K2CO3 (3 mol/L) followed by incubation at 
4°C for 10 min, and centrifugation at 12000 x g for 15 min at 4°C, with the supernatant retained. Serum 
and cellular samples (50 L) and standard solutions of NMN (50 l; 25 – 200 mol/l) were 
subsequently derivatised by addition of 20 l KOH (1 mol/L) and 20 l acetophenone (Sigma, Poole, 
UK) followed by incubation at 4°C for 15 min. Formic acid (90 L) was then added and the solution 
incubated for 10 min at 37°C, producing a highly fluorescent compound. Samples or standards (150 
L) were then added into a 96-well plate fluorescence was detected on a SpectraMax i3x plate reader 




Serum non-reducing immunoblotting was conducted as previously described. Primary antibody 
against NAMPT (both Cell Signaling Technologies, MA, USA) was used in this study (all primary 
antibodies were rabbit anti-mouse polyclonal and were used at 1:1000 dilutions). Immunoblots were 
conducted under non-reducing conditions, where no reducing agent was added to the protein samples 
prior to SDS-PAGE. This allows detection of both monomeric and dimeric eNAMPT in biological 
samples. Densitometry of western blot bands was calculated using Image J Software and densitometry 
data was used to calculate percentage ratio of eNAMPT monomer:dimer in ND and T2D serum. 
Concentrations of monomer and dimer in T2D serum were calculated by taking the total eNAMPT 
concentration present in the sample (as calculated by ELISA) and using the percentages derived from 
densitometry to calculate final serum concentrations of monomer and dimer. Western blots are 
representative of 3 separate blots. sTo ensure equivalent loading of each gel lane, serum protein was 
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Supplementary Table 1 
Primers for qPCR 
Human primers 
Gene Forward primer (5’-3’) Reverse primer (3’-5’) 
IL1β GGCTGCTCTGGGATTCTCTT CCATCATTTCACTGGCGAGC 
CCL2 CACCTGGACAAGCAAACCCA GTGTCTGGGGAAAGCTAGGG 
TNFα GCCCATGTTGTAGCAAACCC TATCTCTCAGCTCCACGCCA 
 
Mouse primers 
Gene Forward primer (5’-3’) Reverse primer (3’-5’) 
GAPDH AGGGCTGCTTTTAACTCTGGT CCCCACTTGATTTTGGAGGGA 
PDX1 GAACCCGAGGAAAACAAGAGG GTTCAACATCACTGCCAGCTC 
INS2 CCGTGGTGAAGTGGAGGA CAGTTGGTAGAGGGAGCAGAT 
NKX2.2 CCTTTCTACGACAGCAGCGA CCGTGCAGCGAGTATTGCAG 
NKX6.1 CAAGGCTGCACATCGTGTTT GAACAGGCTAGGTGGGTCTG 
Il1B GGGCTGCTTCCAAACCTTTG TGATACTGCCTGCCTGAAGCTC 
CCL2 GGCTGGAGAGCTACAAGAGG GGTCAGCACAGACCTCTCTG 







ESM Figure 1: Serum eNAMPT and NMN levels are not correlated with BMI or age. Serum was 
collected from non-diabetic, IFG and type 2 diabetic individuals, and eNAMPT and NMN were 
measured by ELISA and fluorometric assay, respectively. (a) Serum eNAMPT vs BMI (data generated 
from BodyFatS&H and VaSera trial samples); (b) Serum NMN vs serum insulin; (c) Serum eNAMPT 
vs. age (data generated from BodyFatS&H and VaSera trials). (d) Serum NMN vs BMI (data generated 
from BodyFatS&H and VaSera trial samples); (e) Serum NMN vs serum insulin; (f) Serum NMN vs 
age (NMN data generated from VaSera trial only). N is equal to 1 individual. N values differ for NMN 
measurements due to limited sample availability for some samples. Statistics were calculated using 




ESM Figure 2: Structural and functional characterisation of eNAMPT-monomer and eNAMPT-
WT. (a-b) Size exclusion chromatography data showing (a) eNAMPT-WT and (b) eNAMPT-
monomer (SSDD); (c) Native mass spectra of 6.5 M eNAMPT-WT and 5 M eNAMPT-monomer 
(SSDD) in 100 mM ammonium acetate showing differences in the monomer to dimer distribution. (D 
– E) MIN6 cells were incubated with either NMN (100 M), WT-eNAMPT (1 ng/mL) or eNAMPT-
monomer (1 ng/mL) for 48 hours; (d) intra-cellular NMN, (e) intra-cellular NAD (n=5 – 10). (f) 
Endotoxin concentrations in preparations of WT-eNAMPT and eNAMPT-monomer. Data are 











ESM Figure 3: Commercially obtained eNAMPT exerts a bi-phasic effect on glucose-stimulated 
insulin secretion Static insulin secretion in response to basal (2mM) or 20mM glucose was assessed 
in isolated mouse islets incubated with 1 – 5 ng/mL commercially obtained eNAMPT (Adipogen, 
Seoul, South Korea) for (a) 24 hours (n=12), (b) 48 hours (n=6) and (c) 72 hours (n=5). Data are 





















ESM Figure 4: Effects of eNAMPT-WT on islet delta-cell number. Mouse islets were treated with 
1 – 5 ng/mL eNAMPT-WT for 48 h (a) Double immunofluorescence images of islets stained for 
somatostatin (green) and DAPI (blue) (b) % DAPI/SST positive stained cells (n=3); (c) Double 
immunofluorescence images of islets stained for insulin (red) and DAPI (blue) (d) % DAPI/INS 
positive stained cells (n=3); (e) Immunofluorescence images of islets stained for SST (green), INS 
(red) and DAPI (blue) (f) % DAPI/SST:% DAPI/INS stained cells (n=3); Data are expressed as means 







Checklist for reporting human islet preparations used in research  
Adapted from Hart NJ, Powers AC (2018) Progress, challenges, and suggestions for using human islets  
to understand islet biology and human diabetes. Diabetologia https://doi.org/10.1007/s00125-018-4772-2 
 





































































































Unique identifier Unknown Unknown Unknown Unknown Unknown 
Donor age (years) 50 49 26 49 59 
Donor sex (M/F) Male Male Male Female Female 
Donor BMI (kg/m2) Unknown Unknown Unknown Unknown 24 
Donor HbA1c or other 
measure of blood glucose 
control 
Unknown Unknown Unknown Unknown Unknown 










































Donor history of diabetes? 
Please select yes/no from 
drop down list 
No No No No No 
Diabetes duration (years) N/A N/A N/A N/A N/A 
Glucose-lowering therapy at 
time of deathc 
N/A N/A N/A N/A N/A 
RECOMMENDED INFORMATION 







Warm ischaemia time (h) Unknown Unknown Unknown Unknown Unknown 
Cold ischaemia time (h) Unknown Unknown Unknown Unknown Unknown 
Estimated purity (%) 75-80 55 80 70 Unknown 
Estimated viability (%) 85 80 80 80 Unknown 
Total culture time (h)d 72 hours 72 hours 72 hours 120 hours 72 hours 
Glucose-stimulated insulin 























Insulin secretion  
Handpicked to purity? 
Please select yes/no from 
drop down list 
Yes Yes Yes Yes Yes 
Additional notes      
aIf you have used more than eight islet preparations, please complete additional forms as necessary 
bFor example, IIDP, ECIT, Alberta IsletCore 
cPlease specify the therapy/therapies 
dTime of islet culture at the isolation centre, during shipment and at the receiving laboratory 
ePlease specify the test and the results 
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